The Valley Desk

NCT03551782 · Interventional trial

A Study of Cetrelimab (JNJ-63723283), a Programmed Cell Death Receptor-1 (PD-1) Inhibitor, Administered in Combination With Apalutamide in Participants With Metastatic Castration-Resistant Prostate Cancer

Overall registry status Completed

Phase 1

Conditions Castration-Resistant Prostatic Neoplasms

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov